Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells |
Synonyms | |
Therapy Description |
Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells are engineered T cells expressing chimeric antigen receptor consisted of CD19 linked to CD8, CD28, and TCR/CD3-zeta, a co-expressing membrane-bound IL-15 and IL-15 receptor fusion protein (mbIL15), and a truncated EGFR (HER1t), which may lead to cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells | CD19 Immune Cell Therapy 62 | Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells are engineered T cells expressing chimeric antigen receptor consisted of CD19 linked to CD8, CD28, and TCR/CD3-zeta, a co-expressing membrane-bound IL-15 and IL-15 receptor fusion protein (mbIL15), and a truncated EGFR (HER1t), which may lead to cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|